The short answer: the best FDA and regulatory newsletters in 2026 are Pink Sheet and Scrip for deep regulatory and commercial intelligence, Regulatory Focus from RAPS for regulatory affairs professionals, Endpoints News and STAT for major regulatory stories as they break, and BioMed Nexus for a free daily brief that tracks approvals, designations, and decisions as dated events. Which fits depends on whether you need professional depth or a fast, actionable read.
Here is the comparison for a regulatory focused reader.
Comparison chart: regulatory newsletters
| Newsletter | Focus | Format | Price | Best for |
|---|---|---|---|---|
| Pink Sheet / Scrip | Regulatory and commercial intelligence | Regular | Paid | Regulatory strategy and policy depth |
| Regulatory Focus (RAPS) | Regulatory affairs profession | Regular | Membership | Regulatory and quality professionals |
| Endpoints News | Breaking regulatory and industry news | Multiple emails | Freemium | Fast coverage of major decisions |
| STAT | Investigative and policy reporting | Daily and weekly | Freemium | Depth on policy and controversy |
| BioMed Nexus | Regulatory events as dated signals | Daily brief | Free | Tracking approvals and decisions to act on |
What each source is really for
For professional depth, Pink Sheet and Scrip are the references, covering regulatory strategy, policy, and commercial implications in detail for people whose job is submissions and market access.
For the profession itself, Regulatory Focus from RAPS serves regulatory affairs and quality professionals with guidance, standards, and career relevant coverage.
For breaking decisions, Endpoints and STAT cover the major approvals, Complete Response Letters, and controversies as they happen, with STAT going deeper on policy and investigative angles.
For a fast, actionable read, BioMed Nexus tracks designations, acceptances, action dates, approvals, and Complete Response Letters as dated events, which is useful for anyone who needs to act on a regulatory milestone rather than only understand it.
Why regulatory decisions matter beyond compliance
A regulatory milestone is not only a compliance event. It is a commercial one. A target action date is a fixed deadline by which a company must be ready to sell. A facility related Complete Response Letter often means a manufacturing partner is about to be replaced. Reading regulatory news as dated, consequential events, rather than only as compliance updates, is what makes it actionable for commercial and business development teams as well as regulatory ones.
Frequently asked questions
What is the best FDA newsletter?
For professional depth, Pink Sheet and Scrip lead. For breaking coverage, Endpoints News and STAT are strong. For a free daily read that tracks approvals and decisions as dated events, BioMed Nexus is a good fit.
Where do regulatory affairs professionals get news?
Regulatory Focus from RAPS serves the profession directly, and Pink Sheet and Scrip provide deep regulatory and commercial intelligence, with Endpoints and STAT covering major stories as they break.
Is there a free FDA newsletter?
Yes. BioMed Nexus offers a free daily brief that tracks FDA approvals, designations, and decisions, and Endpoints and STAT include major regulatory stories in their free tiers.
How do I track FDA approvals and PDUFA dates?
Several newsletters cover regulatory milestones. BioMed Nexus tracks designations, acceptances, action dates, and approvals as dated events, and specialist paid services offer more detailed regulatory calendars.
Read the BioMed Nexus daily brief
BioMed Nexus is a free daily brief read by more than 65,000 biotech and pharma professionals, tracking FDA approvals, designations, and decisions as the dated events that change what companies do next.
